The shadow of generic rivalry has long loomed around copyright’s famous drug, Sildenafil, triggering questions about the outlook of similar medicinal portfolios. While initial times saw substantial returns, the patent expiration has allowed the door for less expensive copies, likely lowering revenue and posing a significant danger for stakeholder